Publications and Abstracts

Piedmont Research Center employees are shown in bold

Publications

Agrawal, S., Kandimalla,E., Yu,D., Hollister,B.A., Chen,S., Dexter,D., Alford,T., Hill,B., Bailey,K., Bono,C., Knoerzer,D., Morton,P. Potentiation of Antitumor Activity of Irinotecan by Chemically Modified Oligonucleotides. May 2001. 18(5): 1061.* * Hybridon, Inc., Cambridge,MA., Piedmont Research Center Inc., Morrisville, NC., Pharmacia Corp., St.Louis, MO.

Agrawal, S., Kandimalla, ER., Yu D., Ball, R., Lombardi, G., Lucas, T., Dexter, DL., Hollister, BA., and Chen, SF. GEM 231, A Second-Generation Antisense Agent Complementary to Protein Kinase. A Rialpha Subunit, Potentiates Antitumor Activity of Irinotecan in Human Colon, Pancreas, Prostate and Lung Cancer Xenografts. July 2002. 21(1):65-72.

Sands, H., Mishra, A., Stoekler, J., Hollister, BA., and Chen, SF., Preclinical Activity of an I.V. Formulation of Rubitecan in IDD-P Against Human Solid Tumor Xenografts. Oct. 2002. 13(9): 965-75.* * SuperGen , Inc., Dublin, CA.; SkyePharma Canada Inc., Nuns Island, Quebec; Piedmont Research Center, Inc., Morrisville, NC; Roger Williams Hospital, Providence, RI; Brown University, Providence, RI;

Emanuel, S., Gruninger, RH., Fuentes-Pesquera, A., et-al. A VEGF-R2 Kinase Inhibitor Potents the Activity of the Conventional Chemotheraeutic Agents Paclitaxel and Doxorubicin in tumor Xenograft Models. Mol Pharmacol 2004; 66:1-13. * * Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey and Piedmont Research Center, LLC., Morrisville, North Carolina

Lobb, KL., Hipskind, PA., Aikins, JA., Alvarez, E., Cheung, Y-Y., Considine, EL., DeDios, A., Durst, GL., Ferritto, R., Grossman, CS., Giera, DD., Hollister, BA., Hung, Z., Iversen, PW., Kaw, KL., Li, T., Lin, H-S., Lopez, B., Lopez, JE., Martin-Cabrejas, LM., McCann, DJ., Molerom V., Reilly, JE., Richett, ME.m Shih, C., Teicher, B., Wikkel, JH., White, WT., and Mader, MM. Acyl Sulfonamide Anti-Proliferatives: Benzene Substituent Structure-Activity Relationships for a Novel Class of Antitumor Agents. J. Med. Chem 2004; 47, 5367-5380.* * Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana, Albany Molecular Research, Inc., Albany, NY, Centro de Investigacion Lilly, Madrid, Spain, and Piedmont Research Center, Morrisville, NC

Emanuel, S., Rugg, CA., Gruninger, RH., Lin, R., Fuentes-Pesquera, A., Connolly, PJ., Wetter, LK., Hollister, B., Kruger, WW., Napier, C., Jolliffee, L., and Middleton, SA.. The In Vitro and In Vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinase and Aurora Kinases. Cancer Research 2005; 65(19), 9038-9046. October 1, 2005. * * Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey and Piedmont Research Center, LLC., Morrisville, North Carolina

LaMontagne, KR., Butler, J., Marshall, DJ., Tulai, J., Gechtman, Z., Hall, C, Meshaw, A., and Farrell, FX.. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Molecular Cancer Therapeutics; 2006; 5(2), 347-355. February 2006* * Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ; Centocor, Radnor, PA; and Piedmont Research Center, LLC., Morrisville, NC.

Schluep, T., Hwang, J., Cheng, J., Heidel, JD., Bartlett, DW., Hollister, B, and Davis, ME. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models. Clinical Cancer Research; 2006; 12(5), 1606-1614. March 1, 2006* *Insertt Therapeutics, Inc., Pasadena, CA; Chemical Engineering, California Institute of Technology, Pasadena, CA; and Piedmont Research Center, LLC., Morrisville, NC.

Kumar, R., Knick,V.B., Rudolph, S.K., Johnson, J.H., Crosby, R.M., Crouthamel, M.C., Hopper, T.M., Miller, C.G., Harrington, L. E., Onori, J.A., Mullin, R.J., Gilmer, T.M., Truesdale, A.T., Epperly, A.H., Boloor, A., Stafford, J.A., Luttrell, D.K., and Cheung. M. PK-PD correlation from mouse to human with pazopanib, a multi-kinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics, 2007; 6(7), 2012–21. July 1, 2007* * GlaxoSmithKline, Collegeville, Pennsylvania; Piedmont Research Center, LLC., Morrisville, North Carolina

Stuart L. Emanuel, Terry V. Hughes, Mary Adams, Catherine A. Rugg, Angel Fuentes-Pesquera, Peter J. Connolly, Niranjan Pandey5 Sandra Moreno-Mazza, Jeannene Butler, Virna Borowski, Steven A. Middleton, Robert H. Gruninger, Jennifer R. Story, Cheryl Napier, Beth Hollister, and Lee M. Greenberger. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Molecular Pharmacology; 2008; 73(2), 388-348. January 24, 2008* * Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey and Piedmont Research Center, LLC., Morrisville, North Carolina

Richard A. Kenley, Mikhail F. Denissenko, Robert J. Mullin, Jennifer Story and Jonas Ekblom. Formoterol Fumarate and Roxithromycin Effects on Muscle Mass in an Animal Model of Cancer Cachexia. Oncology Reports; 2008; 19: 1113-1121. May 2008 * * Anaborex, Inc., Carlsbad, CA, Piedmont Research Center, LLC., Morrisville, NC, The Releef Initiative, Glendale, CA

Karen Clark, Beth Hollister. The Role of Hands-On Science and Research Curriculum in the Formation of Science Opinions in Middle School Students. Teaching Science Ethics in Animal Research. (National Science Teachers Association) New Orleans, LA;March 2009. * *Immaculata Catholic School, Durham, NC; Piedmont Research Center, LLC., Morrisville, NC

Abstracts

Wajima, M., Mangold, G., Hollister, BA., Koreeda, M., Shull, B., Dexter, DL., Von Hoff, DD. and Chen, SF.. Biological Evaluation of Novel Series of Glycosylated Camptothecin Analogs, (EORTC-International Conference, Amsterdam). American Cancer for Cancer Research. Washington, DC. April 1996. #2963, p434.

Principe, P., Marsals, J., Kasprzyk, P.G., Carlson, M., Lauer, J., Meshaw, K., Alford, T., Hill, B., Chen, SF., Hollister, B.A., and Dexter, D.L. Anti-Tumor Profile of BN80915, A novel E-ring modified topisomerase I inhibitor, (AACR-NCI-EORTC-International Conference). Washington, DC. November 1999. #664, p135.

Kasprzyk, PG; Lauer, J; Carlson, M; Demarquay, D; Lavergne, O; Principe, P; Bigg, D; Dexter, D; Chen, SF; Hollister, BA; Alford, T; and Meshaw, K. In Vivo Anti-Tumor Activity of a Dual Topoisomerase I/II Inhibitor, BN80927, Against Human Tumor Xenografts, (American Association for Cancer Research). San Francisco, CA. March 2000. 41:#1342, p210.

Kasprzyk, PG; Carlson, J; Lauer, AS; Meshaw, K; Alford, T; Hill, BP; Chen, SF; Hollister, BA; Dexter, D; Marsais, J; and Principe, P. Anti-Tumor Activity of Orally Administered BN80915, A Novel Topisomerase-I Inhibitor, In Xenograft Models (American Association for Cancer Research). San Francisco, CA. March 2000. 41:#5201 p819.

Howard, S., Mishra, AK., Hollister, BA., Alford, T., Ball,R., and Chen, SF. Pre-Clinical Antitumor Activity of 9-Nitrocamptothecin (9NC) in Proprietary IDD-PTM and IDD-DTM Formulation, (American Association for Cancer Research). New Orleans, LA. March 2001. 42:# 552 p102.

Kandimalla, ER., Yu, D., Hill, B., Alford, TL., Dexter, DL., Chen, SF., Hollister, BA., Agrawal, S., Proteintiation of Antitumor Activity of Irinotecan by Co-administration of Chemically Modified Oligonucleotiede in Pancreatic, Colon, and Melanoma Tumor Models. (American Association for Cancer Research). New Orleans, LA. March 2001. 42:# 555 p102.

Westlin, WF., Griggs, DW., Engleman, VW., Keene, JL., Duffin, TD., Settle, SL., Nickols, MA., Hollister, BA., Knoerzer, DL., Meyer, DM., Pegg, JA., Ruminski, PG., Rogers, TE., Russell, MA., Nickols, GA. Pharmacological Characterization of a Novel Orally Active Angiogenesis Inhibitor, S-137: An Antagonist of the Integrin αVβ3. (American Association for Cancer Research). New Orleans, LA. March 2001. 42:# 3159 p588.

Kasprzyk, PG., Lauer, J., Savola, A., Alford, T., Lombardi, G., Hollister, BA., Chen, SF., Dexter, DL., and Principe, P. I.V. Activity of BN-80915 on Five Different Schedules in Three Human Tumor Xenograft Models. (American Association for Cancer Research). New Orleans, LA. March 2001. 42:#3864 p719.

Carron, CP., Becker, D., Duffin, T., Goellner, J., Knoerzer, D., Mehta, P., Munie, G., Funckes-Shippy, C., Swearingen, C., Villamil, C., Welsch, D., Zhang, K., Hollister, BA., Dexter, DL., DeCrescenzo, G., and McWherter, C. The Highly Selective MMP-1 Sparing Matrix Metalloproteinase Inhibitor SC-77964 Provides Broad Spectrum Anti-Tumor Activity. (American Association for Cancer Research). New Orleans, LA. March 2001. 42:#4975 p.926.

Emanuel, S., Grunuinger, R., Lin, R., Rugg, C., Fuentes-Pesquera, A., Conolly, P., Wetter, S., Hollister, BA., Kruger, W., Napier, C., Johnson, D., Jolliffe, L., and Middleton, S. Inhibition of Human Tumor Xenograft Growth by a Novel, Potent and Selective CDK Inhibitor. (American Association for Cancer Research). San Francisco, CA 2002. * * Johnson & Johnson, NJ; Piedmont Research Center, Inc., Morrisville, NC

Hollister, BA., Chen, SF., Meshaw, K., Kesterson, J., Metts, L., Abramowitz, R., and Holton, R. A New Taxane With Curative Antitumor Activity Against Human Tumor Xenografts. (American Association for Cancer Research). San Francisco, CA 2002. * * Piedmont Research Center, Inc., Morrisville, NC.; Taxolog, Inc., Jacksonville, FL.; Taxolog, Fairfield, NJ.; Florida State University, Tallahassee, FL.

Holton, R., Metts, L., Kesterson, J., Abramowitz, R., Hollister, BA., Meshaw, K., and Chen, S. Oral Anti-Tumor of TL00139(MAC-321) -A New Taxane (American Association for Cancer Research). San Francisco, CA 2002. * * Florida State University, Tallahassee FL.; Taxolog, Inc., Fairfield, NJ.; Taxolog, Inc.; Jacksonville, FL.; Piedmont Research Center, Inc., Morrisville, NC.

Kaiser, R.M., Napier, C., Collins,G., Hollister, B.A., and Chen, SF. Metronomic Dosing with Camptosar Against Human Colon Tumor Xenografts. (American Association of Cancer Research). San Francisco, CA 2002. * * Piedmont Research Center, Inc., Morrisville, NC.

Van Laar, ES., Kelner, MJ., Woldetsadik, T., Hollister, BA., MacDonald, JR., and Waters, SJ. Enhanced Antitumor Activity of Irofulven in Combination with Gemcitabine Against the MV522 Human Lung Carcinoma Xenograft (American Association for Cancer Research). San Francisco, CA 2002. #85: * * MGI Pharma, Inc., Bloomington, MN.; Department of Pathology, University of California, San Diego, CA.; Piedmont Research Center Inc., Morrisville, NC.

Emanuel, S., Rugg, C., Lin, R., Connolly, P., Napier, C., Hollister, BA., Hall, C., and Middleton, S.. Evaluation of the CDK Inhibitor JNJ-7706621 as a Targeted Antitumor Agent. (American Association for Cancer Research). San Francisco, CA 2002 * * Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ; Piedmont Research Center, Inc., Morrisville, NC.

Emanuel S, Gruninger, RH, Fuentes-Pesquera, A, Connolly, PJ, Seamon, JA, Hazel, S, Tominovich, R, Hollister B.A., Napier C, D'Andrea, MR, Reuman, M, Bignan, G, Tuman, R, Johnson, D, Moffatt, D, Batchelor, M, Foley, A, O'Connell, J, Allen, R, Perry, M, Jolliffe, L, and Middleton, SA.. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models. (American Association for Cancer Research). Orlando, FL. April 2004. * * Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ.; Piedmont Research Center Inc., Morrisville, NC.

Steed, S., Mahoney, R., Galasinski, S., Evans-Storm, R., Cheatham, L., Story, J., Chen , SF., Harrison, S., Avrutskaya, A., Hollister, BA., Williams, K., Janzen,W., Dickson, J.K., and Hodge, CN. The Anti-Proliferative Activity of Potent and Highly Selective Inhibitors of AKT1. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Amphora Discovery Corp., RTP, NC.; Piedmont Research Center, Inc., Morrisville, NC

Emanuel, S., Gruninger, R., Fuentes-Pesquera, A., Conolly, P.J., Seamon, JA., Hazel, S., Tominovich, R., Hollister, BA., Napier, C., D’Andrea, M., Reuman, M., Bignan, G., Tuman, R., Johnson, D., Moffatt, D., Batchelor, M., Foley, A., O’Connell, J., Allen, R., Perry, M., Jolliffe, L., and Middleton, S. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Johnson & Johnson, Raritan, New Jersey; Institute of Medical and Veterinary Science, Adelaide, Australia; Piedmont Research Center, Inc., Morrisville, NC.; Celltech Research, Limited, Slough, United Kingdom

Emanuel, S., Hazel, S., Fuentes-Pequera, A., Gruninger,R., Seamon, J., Connolly, P., Kaiser, R., Napier, C., Hollister, BA., and Middleton, S. Inhibition of Angiogenesis and Retinal Neovascularization by an Orally Available Vascular Endothelial Growth Factor Receptor Inhibitor. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Johnson and Johnson, Raritan, NJ; Institute of Medical and Veterinary Science, Adelaide, Australia; Piedmont Research Center, Inc., Morrisville, NC.

Schluep, T., Jensen, G., Chen, J., Heidel, J., Bartlett, D., Hu, S., Triche, T., and Davis, M.. Camptothecin-polymer Conjugate Shows Improved Biodistribution and Preclinical Efiicacy. (American Assoication for Cancer Research). Anaheim, CA. April 2005. * * Insertt Therapeutics, Pasadena, CA; California Institute of Technology, Pasadena,CA; Childrens Hospital, Los Angeles,CA; Piedmont Research Center, Inc. collaboration acknowledgement

Hu-Lowe, D., Grazzani, M., Chen, J., Zhang, J., Zhong, WZ., Laird, D., and Patyna, S.. SU014813 Is a Novel Multireceptor Tyrosine Kinase Inhibitor With Potent Antiangiogenic and Antitumor Activity. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Pfizer Global Research and Development,San Diego,CA; Pfizer, La Jolla,CA, Sugen, Inc., San Francisco,CA; Piedmont Research Center, Inc. collaboration acknowledgement

Hu-Lowe, D., Grazzani, M. Significant Enhancement of Antitumor Efficacy of VEGF/PDGF Receptor Tyrosine Kinase Inhibitor AG-013736 in Combination with Docetaxel in Chemorefractory and/or Orthotopic Xenograft Tumor Models in Mice. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Pfizer Global Research and Development, San Diego,CA; Piedmont Research Center, Inc. collaboration acknowledgement

McLean, B., Kapdee, B., Khuu,W., Restelli,V., Wong, J., Amandoron, E., Zimmerman,C., Webb, N., Whiteway, JA., Stoll, D., Purac, A., Braun,C., and Borgford, T.. Prostate Specific Antigen-Activated Type II Ribosome-Inactivating Protein-Based Prodrugs for the Targeted Treatment of Prostate Cancer. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Twinstrand Therapeutics, Inc., Burnaby, British Columbia, Canada; Piedmont Research Center, Inc. collaboration acknowledgement

Carter, T., Trieber, DK., Biggs,WH., Fabian, MA., Valasco, AM., Edeen, PT., Ford, JT., Milanov, ZV., Mehta, SA., Grotzfeld, RM., Lai, AG., Ciceri, P., Floyd, M., Insko,DE., Herrgard, S., Atteridge, CE., Wodicka, LM., Patel, HK., Zarrinkar, PP., and Lockhart, DJ.. Identification and Characterization of Highly Potent and Specific FLT3 Kinase Inhibitors Effective Against FLT3-Driven Leukemia in Culture and In Vivo. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Ambit Biosciences, San Diego, CA; Piedmont Research Center, Inc. collaboration acknowledgement

Durham, W., Hall, C., Ball, R.. Mouse Model of Docetaxel Neurotoxicity: Preclinical Pharmacology of New Agents. (American Association for Cancer Research). Anaheim, CA. April 2005. * * Piedmont Research Center, Inc., Morrisville, NC

Grant, M; Hollister, B; Parker, G; Story, J. The Occurrence of Anasarca in Athymic Nude Mice on Two Different Genetic Backgrounds. (American Association for Laboratory Animal Science) 2005. * * Piedmont Research Center, LLC., Morrisville, NC

Stuart L. Emanuel, Catherine A. Rugg, Ronghui Lin, Robert H. Gruninger, Peter J. Connolly, Steven A. Middleton, Cheryl Napier, Beth Hollister, Linda Jolliffe, Lee Greenberger.. Preclinical Profile of JNJ-7706621: A Duel Cyclin Dependent Kinase and Aurora Kinase Inhibitor. (American Association for Cancer Research ). Washington, DC. April 2006. * * Johnson & Johnson, Raritan, NJ; Piedmont Research Center, LLC. collaboration acknowledgement

Story, J; Grant, M; Gilliard, G; Turner, W; Salters, J; Salters, J; Hollister, B; Arneson, D; and Thigpen, J. RODAC Plates Containing 5% Sheep Blood Improved Detection of Staphylococcus aureus in Rooms Housing Athymic Nude Rodents (American Association for Laboratory Animal Science) 2006. * Piedmont Research Center, LLC., Morrisville, NC

Ian Kasman, Anil Bagri, Judy Mak, Franklin Peale, Rick Carano, Jed Ross, Leanne Berry, Young Shin, Patrick Rudewicz, Cary Austin, Ronald Ferrando, Sarajane Ross, Lisa Crocker, Nicolas Van Bruggen, Harriet Pais, Kurt Scudder, Beth Hollister, Greg Plowman. Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy (American Association for Cancer Research). San Diego, CA. April 2008. #2494 * * Genentech, Inc., South San Francisco, CA, Genentech, Inc., South San Francisco, CA, Definiens, Inc., Morristown, NJ, Piedmont Research Center, LLC. Morrisville, NC

Laura C. Akullian, John J. Kane, Alex Yurkovetskiy, Mao Yin, Russell C. Petter, Charles E. Hammond, Cheri A. Stevenson, Robin Adams, Cheryl Napier, Robert J. Fram. Fumagillin-derived polymeric pro-drugs exhibit anti-tumor activity in B16 murine melanoma and in A2058 and PC3 human tumor xenograft models. (American Association for Cancer Research). San Diego, CA. April 2008. 30:#2327 * * Mersana Therapeutics, Cambridge, MA, Piedmont Research Center, LLC. Morrisville, NC

Sacha J. Holland, Yuanming Hu, Betty Chang, Alison Pan, Christian Franci, Weiqun Li, Matt Duan, Arthur Bagos, Allan Torneros, John McLaughlin, Jing Zhang, Jiaxin Yu, Pingyu Ding, Thilo J. Heckrodt, Joanne Litvak, Emily Stauffer, Ayodele Apatira, Din-Lii Lin, Ashley Morgan, George Clemens, Sarkis Daniel-Issakani, Polly Pine, Dane Goff, Rajinder Singh, Donald G. Payan, Yasumichi Hitoshi. Suppression of tumor growth and angiogenesis by novel small molecule inhibitors of the axl receptor tyrosine kinase. (American Association for Cancer Research). San Diego, CA. April 2008. 30:#4866 * * Rigel, Inc., South San Francisco, CA, Piedmont Research Center, LLC. Morrisville, NC collaboration acknowledgement

Sara L. Zaknoen, Tracy L. Lawhon, Mary Ann Meade, Richard R. Leopold III, Andrew K. Wong, Kathryn R. Meshaw, Randall K. Johnson. Activity of TG01, a selective COX-2 inhibitor, alone and in combination with standard agents in human breast carcinoma xenografts. (American Association for Cancer Research). San Diego, CA. April 2008. 30:#5662 * * Tragara Pharmaceuticals, San Diego, CA, MIR Preclinical Services, Ann Arbor, MI, Piedmont Research Center, LLC. Morrisville, NC, Independent Consultant, Santa Fe, NM

Tracy L. Lawhon, Sara L. Zaknoen, Andrew J. Wong, Kathryn R. Meshaw, Randall K. Johnson. Activity of TG01, a selective COX-2 inhibitor, alone and in combination with docetaxel in human non-small cell lung carcinoma xenografts. (American Association for Cancer Research). San Diego, CA. April 2008. 30:#5663 * * Tragara Pharmaceuticals, San Diego, CA, Piedmont Research Center, LLC. Morrisville, NC, Independent Consultant, Santa Fe, NM

James G. Christensen, Beth A. Hollister. Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. (American Association for Cancer Research). San Diego, CA. April 2008. 29:#1433 * * Pfizer Global Research and Development, La Jolla, CA

Gail D. Lewis Phillips, Carter T. Fields, Lisa Crocker, Kathryn Parsons, Jay Tibbitts, Scott Holden, Stuart Lutzker, Mark X. Sliwkowski. Potent anti-tumor activity of trastuzumab-DM1 antibody-drug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. (American Association for Cancer Research). San Diego, CA. April 2008. 8:#2133 * * Genentech, Inc., South San Francisco, CA, Piedmont Research Center, LLC. Morrisville, NC collaboration acknowledgement.

Mark A. Wolf, Randall K. Johnson, Dejian Xie, Anna Avrutskaya, Robert Mullin, Beverly Godfrey, Ian Scott. In vivo evaluation of ALB 109564, a novel tubulin inhibitor with improved efficacy over existing members of the vinca alkaloid class. (EORTC-NCI-AACR). Geneva, Switzerland. October 2008. * * AMRI, Albany, NY; Santa Fe, NM; Piedmont Research Center, LLC. Morrisville, NC

Jennifer Story, Julius Thigpen, Andrew Wong, LaKesha Reid, Terri Frost, Beth Hollister, Mary Grant, Lynn Cheatham, Kay Meshaw. Mycoplasma arginini Associated with Swollen Joints in Severe Combined Immunodeficient Mice Implanted with Tumor Cells. (American Association for Laboratory Animal Science) 2008. * * Piedmont Research Center, LLC., Morrisville, NC

Karen Clark, Beth Hollister. The Role of Hands-On Science and Research Curriculum in the Formation of Science Opinions in Middle School Students. Teaching Science Ethics in Animal Research. (National Science Teachers Association) New Orleans, LA; March 2009. * *Immaculata Catholic School, Durham, NC; Piedmont Research Center, LLC., Morrisville, NC

Paul M. Steed, Bruce Oberhardt, Chris Luft, Mei Hu, Stephen A. Lommel, Stefan Franzen, Dick Guenther, Dustin Lockney, Steadman D. Harrison, Kathryn Meshaw, Elizabeth Rainbolt. A safe, biology-based nanocarrier delivers anti-tumor cargo specifically to cancer cells in vitro and in vivo. (American Association for Cancer Research). Denver, CO. April 2009. 38:#3790 * * Nanovector, Inc., Chapel Hill, NC. North Carolina State University, Raleigh, NC, Piedmont Research Center, LLC, Morrisville, NC

Dana D. Hu-Lowe, Adam Mathias, Chassidy Hall, Enhong Chen, Lianglin Zhang, Robert Mullin, Beth Hollister, Jamie Christensen. Impact of dosing schedule and dosing sequence on anti-tumor efficacy of combination therapy with the antiangiogenic agent (AA) axitinib (AG-013736) in xenograft tumor models of human pancreatic carcinoma and non-small cell lung cancer (NSCLC). (American Association of Cancer Research). Denver, CO. April 2009. 6:#144 * * Pfizer Global Research and Development, San Diego, CA, Piedmont Research Center, LLC, Morrisville, NC.

Deborah Anderson, Cheryl Napier, Anna Avrutskaya, Angela White, Tracy Pheneger, Jim Walker, Patrice A. Lee. In vivo activity of ARRY-334543: A potent, small molecule inhibitor of EGFR/ErbB2 in combination with trastuzumab or docetaxel. (American Association of Cancer Research). Denver, CO. April 2009. 35#1757 * * Array BioPharma Inc., Bolder, CO, Piedmont Research Center, LLC, Morrisville, NC.

Patrice A. Lee, Cheryl Napier, Jennifer Garrus, Anna Avrutskaya, Angela White, Jim Walker. In vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2 in combination with trastuzumab or docetaxel in a BT474 human breast carcinoma xenograft model. (American Association of Cancer Research). Denver, CO April 2009. 35#1757 * * Array BioPharma Inc., Bolder, CO, Piedmont Research Center, LLC, Morrisville, NC.

Russell C. Petter, Erica Evans, Margit Hagel, Russell Karp, Mariana Nacht, Michael Sheets, Thia St. Martin, William Westlin, and Juswinder Singh. A novel small-molecule drug platform to silence cancer targets –Application to the pan-ErbB kinases. (American Association of Cancer Research). Denver, CO. April 2009. 30# 3746 * * Avila Therapeutics Inc., Waltham, MA, Piedmont Research Center, LLC, Morrisville, NC. collaboration acknowledgement.

Mark A. Wolf, Randall K. Johnson, Dejian Xie1, Anna Avrutskaya, Robert Mullin, Beverly Godfrey, Mary Anne Mead, Erin E. Trachet4, Wilbur R. Leopold, Peter Guzzo1, Ian Scott. ALB-109564, a novel tubulin inhibitor with improved efficacy over vinorelbine, is better tolerated when dosed iv versus ip, leading to improved activity in human tumor xenograft studies. (NCI-AACR-EORTC). Boston, MA. November 2009. * * Albany Molecular Research, Inc., Albany, NY; Santa Fe, NM, Piedmont Research Center, Morrisville, NC, MIR Preclinical Services, Ann Arbor, MI.

Li Liu, Anna Avrutskaya, Beverly Godfrey, Carmella C. Britt, Alan Meshaw, Robert J. Mullin, Tona Gilmer. Anti-tumor activity of lapatinib as a single agent and in combination with capecitabine in a HER2-amplified human gastric tumor model (NCI-AACR-EORTC) Boston, MA. November 2009. * * GlaxoSmithKline, Translational Research, King of Prussia, PA and RTP, NC, Piedmont Research Center, Morrisville, NC 27560.

Andrew J. Massey, Stephen Stokes, Helen Browne, Jennifer Borgognoni, Nicolas Foloppe, Simon Scrace, Rob Howes, Andrea Fiumana, Simon Bedford, Paul Webb, Stuart Ray, Allan Jordan, Martin J. Drysdale and Mike Wood. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor-induced apoptosis in HCT116 colon carcinoma cells. (NCI-AACR-EORTC) Boston, MA. November 2009. * * Vernalis R&D Ltd, Granta Park, Cambridge, UK, Piedmont Research Center, Morrisville, NC collaboration acknowledgement.

Li Liu, Yuan Liu, Hong Shi, James Greger, Anne-Marie Martin, Tona Gilmer. The effects of foretinib on MET phosphorylation, gene expression, cell proliferation and tumor growth in MET-amplified tumor cells in vitro and in vivo. (NCI-AACR-EORTC) Boston, MA. November 2009.* * GlaxoSmithKline, Translational Research, King of Prussia, PA, Biomarkers and Translational Medicine, Collegeville, PA, Translational Research, Research Triangle Park, NC and Piedmont Research Center, Morrisville, NC collaboration acknowledgement.

Andrew J. Massey, Stephen Stokes, Helen Browne, Jennifer Borgognoni, Nicolas Foloppe, Simon Scrace, Rob Howes, Andrea Fiumana, Simon Bedford, Paul Webb, Stuart Ray, Allan Jordan, Martin J. Drysdale and Mike Wood. Checkpoint abrogation and potentiation of cytotoxic chemotherapeutics with a novel checkpoint kinase 1 inhibitor. (NCI-AACR-EORTC) Boston, MA. November 2009. * * Vernalis R&D Ltd, Granta Park, Cambridge, UK, Piedmont Research Center, Morrisville, NC collaboration acknowledgement.

Gulledge, T., Blackwell, A. R., Mullin, R., Hollister, B., and Cheatham, L.A. Differential Sensitivity to Dietary Restriction in Xenograft Models harboring PI3K Pathway mutations in Nude Mice. (American Association of Cancer Research) Washington, D.C. April 2010. * * Piedmont Research Center, Morrisville, NC 27560.